CIAS
IRWD icon

Capital Investment Advisory Services’s Ironwood Pharmaceuticals IRWD Stock Holding History

Capital Investment Advisory Services’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,185
Closed -$13K – 1418
2019
Q2 		$13K Buy
+1,185
New +$13.3K ﹤0.01% 893

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Investment Advisory Services's IRWD Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2019, closing a stake of 1,185 shares — an estimated $13K sold.

Capital Investment Advisory Services first reported a position in IRWD in Q2 2019 and held it in 1 quarter. The position peaked at $13K in Q2 2019. 164 funds tracked by Wall St. Rank hold IRWD as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Ironwood Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 1,185 Ironwood Pharmaceuticals shares in Q3 2019, an estimated $13K.
  • Capital Investment Advisory Services first reported a position in Ironwood Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Ironwood Pharmaceuticals position peaked at $13K in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.